# Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients

> **NCT01654653** · PHASE4 · COMPLETED · sponsor: **Innogene Kalbiotech Pte. Ltd** · enrollment: 100 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** Hypertonic sodium lactate
- **DRUG:** 6% Hydroxy Ethyl Starch

## Key facts

- **NCT ID:** NCT01654653
- **Lead sponsor:** Innogene Kalbiotech Pte. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01654653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01654653, "Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01654653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*